Hochhauser E, Barak Y, Einav S, Cohen S, Vidne B
Departments of Physiology, Pharmacology, and Cardiac Surgery, Ichilov Medical Center, Tel-Aviv, Israel.
Tex Heart Inst J. 1986 Mar;13(1):61-7.
In this study, we determined whether pre-ischemic enhancement of the ATP level and the addition of verapamil (a calcium blocker) to the cardioplegic solution could improve myocardial protection during cardiac arrest. Using the Langendorff preparation of the isolated rat heart plus different cardioplegic solutions, five groups of normal rat hearts and five groups of hypertrophied rat hearts were subjected to 90-minute ischemic periods at 28 degrees +/- 1 and reperfusion of 30 minutes at 37 degrees C. Group A received no cardioplegic solution; Group B received KCl, 30 mEq/L; Group C received type B perfusion with verapamil; and Group D received 15 minutes of pre-ischemic oxygenated enhancement perfusion containing KCl, 30 mEq/L, and glucose as substrate at 37 degrees C. Group E received the same perfusion as Group D, with the addition of verapamil to the enhancement perfusion. Light and E/M microscopy was performed on representative samples of left ventricular muscle. We found that pre-ischemic enhancement with KCl, glucose, and verapamil was only protective in the normal hearts after 90 minutes of ischemia. In hypertrophied hearts, the addition of verapamil to the enhancement solution was harmful. The use of pre-ischemic enhancement solution without verapamil provided the best myocardial protection after 90 minutes of ischemia in the hypertrophied hearts.
在本研究中,我们确定了缺血前ATP水平的提高以及在心脏停搏液中添加维拉帕米(一种钙阻滞剂)是否能改善心脏骤停期间的心肌保护作用。使用离体大鼠心脏的Langendorff灌流装置加不同的心脏停搏液,将五组正常大鼠心脏和五组肥大大鼠心脏在28℃±1℃下进行90分钟的缺血处理,并在37℃下再灌注30分钟。A组未接受心脏停搏液;B组接受30 mEq/L的KCl;C组接受含维拉帕米的B型灌注液;D组在37℃下接受15分钟的缺血前充氧强化灌注,灌注液含有30 mEq/L的KCl和作为底物的葡萄糖。E组接受与D组相同的灌注,在强化灌注中添加维拉帕米。对左心室肌肉的代表性样本进行光镜和电镜检查。我们发现,在正常心脏中,缺血前用KCl、葡萄糖和维拉帕米进行强化处理在缺血90分钟后仅具有保护作用。在肥大心脏中,向强化溶液中添加维拉帕米是有害的。在肥大心脏中,缺血90分钟后,使用不含维拉帕米的缺血前强化溶液可提供最佳的心肌保护。